A better understanding of such checkpoints could lead to new approaches for the treatment of chronic inflammatory diseases that are fueled by aberrant RIPK1-induced cell death, and/or reveal novel strategies for anti-cancer immunotherapies that harness RIPK1’s ability to trigger immunogenic cell death (Yatim et al., 2015). The gene discussed is RIPK1; the disease is cancer.